spironolactone has been researched along with Precancerous Conditions in 1 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Precancerous Conditions: Pathological conditions that tend eventually to become malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We determined the effects of SR alone or in combination with the antioxidant α-glycosyl isoquercitrin (AGIQ) on hyperlipidemia- and steatosis-related precancerous lesions in high-fat diet (HFD)-fed rats subjected to a two-stage hepatocarcinogenesis model." | 1.48 | Spironolactone in Combination with α-glycosyl Isoquercitrin Prevents Steatosis-related Early Hepatocarcinogenesis in Rats through the Observed NADPH Oxidase Modulation. ( Eguchi, A; Hayashi, SM; Kawashima, M; Kimura, M; Koyanagi, M; Makino, E; Maronpot, RR; Mizukami, S; Murayama, H; Nagahara, R; Nakamura, M; Ohtsuka, R; Shibutani, M; Takahashi, N; Yoshida, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Murayama, H | 1 |
| Eguchi, A | 1 |
| Nakamura, M | 1 |
| Kawashima, M | 1 |
| Nagahara, R | 1 |
| Mizukami, S | 1 |
| Kimura, M | 1 |
| Makino, E | 1 |
| Takahashi, N | 1 |
| Ohtsuka, R | 1 |
| Koyanagi, M | 1 |
| Hayashi, SM | 1 |
| Maronpot, RR | 1 |
| Shibutani, M | 1 |
| Yoshida, T | 1 |
1 other study available for spironolactone and Precancerous Conditions
| Article | Year |
|---|---|
Spironolactone in Combination with α-glycosyl Isoquercitrin Prevents Steatosis-related Early Hepatocarcinogenesis in Rats through the Observed NADPH Oxidase Modulation.
Topics: Animals; Body Weight; Diet, High-Fat; Drug Therapy, Combination; Fatty Liver; Liver Neoplasms, Exper | 2018 |